<DOC>
	<DOCNO>NCT01549977</DOCNO>
	<brief_summary>The purpose study evaluate effect febuxostat , daily ( QD ) , compare placebo add stable anti-anginal therapy , total exercise time participant Chronic Stable Angina .</brief_summary>
	<brief_title>Effect Febuxostat Compared Placebo Exercise Tolerance Participants With Chronic Stable Angina</brief_title>
	<detailed_description>This phase 2 multicenter , randomize , placebo-controlled double-blind study . This study comprise single-blind placebo run-in qualify phase last approximately 3 week double-blind treatment phase last 12 week . A safety follow-up visit schedule 2 week last dose study drug . All participant undergo 3 visit 3 week , run-in phase ( Days -21 Day 1 ) . During run-in phase , participant receive single-blind placebo . Two exercise treadmill test ( ETTs ) conduct use modify Bruce Protocol Day -14 Day -7 . The result Day -7 ETT consider Baseline . A total approximately 100 participant randomize 1:1 receive either febuxostat 80 mg daily ( QD ) placebo QD double-blind treatment 12 week , 5 visit . All participant complete Seattle Angina Questionnaire ( SAQ ) Euroqol 5 dimension ( EQ-5D ) quality-of-life measurement Day 1 , Week 6 Week 12/Early Termination ( ET ) Visit . The investigator also rate overall severity participant 's angina visit base Canadian Cardiovascular Society Grading Angina ( CCSGA ) . This 12-week phase 2 proof-of-concept study design assess effect febuxostat add-on stable anti-anginal therapy total exercise time participant chronic stable angina serum urate ≥5 mg/dL . At time , Takeda decide terminate study business reason .</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative , sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . The participant serum urate ( sUA ) ≥5.0 mg/dL . 4 . The participant history angina , define : 1 . Minimum 3month history stable angina ( least 2 episode chest pain anginal equivalent past 30 day ) ; AND 2 . Receiving least one chronic antiischemic medication ( ) , include beta blocker , calcium channel blocker long act nitrate ( dos must stable least 30 day prior Screening [ Day 21 ] ) ; AND 3 . Coronary artery disease , define : ≥50 % stenosis ≥1 major coronary artery confirm angiography ; OR Documented prior myocardial infarction ( MI ) enzymes/electrocardiogram ( ECG ) change ; OR Documented myocardial imaging stress test ; OR Prior history coronary artery bypass graft ( CABG ) percutaneous coronary intervention ( PCI ) great 3 month prior Screening Day 21 . 5 . The participant estimate glomerular filtration rate ( eGFR ) &gt; 30 mL/min Modification Diet Renal Disease ( MDRD ) Screening visit Day 21 . 6 . The participant normal/controlled blood pressure Day 1/Randomization , define mean three sit blood pressure exceed 140/90 . 7 . The participant male female age 18 85 year , inclusive . 8 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study . 9 . Participant stable ( 30 day ) medication dose prescribe underlying medical condition ( ie ; hypertension , angina ) remain stable dos throughout study duration . 10 . Participant able take , ongoing manner , nitroglycerine anginal symptom . 11 . Symptomlimited exercise duration , ETT Day 14 Day 7 , modify Bruce Protocol . 12 . Exercise duration two ETTs Day 14 Day 7 differ 20 % long two time , differ 60 second . To confirm Core ECG Lab prior subject randomize . 13 . Definite ECG sign ischemia ETT Day 14 Day 7 ( i.e. , 1 additional mm horizontal downsloping STsegment depression beyond baseline ≥1 mm isoelectric line ) present least one standard ECG lead ETT . The Day 7 ≥1 mm STsegment depression must verify Core ECG Lab prior participant randomize . 1 . The participant receive investigational compound within 30 day prior Screening Day 21 . 2 . The participant receive allopurinol febuxostat previous clinical study therapeutic agent . 3 . The participant gout secondary hyperuricemia ( e.g. , due myeloproliferative disorder , organ transplant ) experience gout flare . 4 . The participant history xanthinuria . 5 . The participant immediate family member , study site employee , dependent relationship study site employee involve conduct study ( e.g. , spouse , parent , child , sibling ) may consent duress . 6 . The participant history hypersensitivity allergy febuxostat nitroglycerine . 7 . The participant hemoglobin &lt; 10 g/L Screening Day 21 . 8 . The participant systolic blood pressure le 100 mmHg . 9 . The participant blood pressure great 200/100 Screening Runin visit . 10 . The participant history clinical manifestation significant medical condition might affect his/her ability complete study . 11 . The participant follow Screening Runin visit : 1 . Resting STsegment depression ≥1 mm lead . 2 . Left bundlebranch block . 3 . New York Heart Association Class III IV heart failure . 4 . Acute coronary syndrome coronary revascularization procedure within 3 month Screening . 5 . WolffParkinsonWhite syndrome . 6 . Pacemaker implantable cardioverter defibrillator . 7 . Arrhythmias ( i.e. , SVT , atrial fibrillation/flutter , VT , rate relate bundle branch block ) . 8 . Left ventricular hypertrophy repolarization abnormality . 12 . The participant recent history ( within last 3 month ) myocardial infarction , heart failure , coronary artery bypass graft , percutaneous coronary intervention , hypertensive encephalopathy , cerebrovascular accident , transient ischemic attack . 13 . The participant contraindication use nitrate ( severe anemia , increase intracranial pressure , know sensitivity hypersensitivity nitroglycerin ingredient , nitrate nitrite ; concomitant use either regularly and/or intermittently , phosphodiesterase type 5 ( PDE5 ) inhibitor ) . 14 . The participant unstable angina : 1 . Occurs participant rest . 2 . Is prolonged , usually great 20 minute . 3 . Occurs increase intensity , duration , and/or frequency . 4 . Responds poorly nitroglycerin ( i.e. , go away three dos nitroglycerin return nitroglycerin help first ) . 15 . The participant unable exercise sufficiently complete ETT due leg claudication , arthritis , deconditioning , associate pulmonary disease . 16 . The participant severe critical valvular disease document echocardiogram , congenital heart disease . 17 . The participant leave ventricular ejection fraction ( LVEF ) less 35 % , document echocardiogram angiography . 18 . The participant clinically significant cardiac conduction defect ( i.e. , second thirddegree atrioventricular block , sick sinus syndrome QTc &gt; 500 msec ) Day 21 . 19 . The participant active acute myocarditis/pericarditis within 3 month prior Screening Day 21 . 20 . The participant hypertrophic cardiomyopathy . 21 . The participant alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level great 2.0 time upper limit normal , active liver disease , jaundice . 22 . The participant history drug abuse ( define illicit drug use ) history alcohol abuse within 5 year prior Screening Visit . 23 . The participant require expect require exclude medication digoxin digoxincontaining compound . 24 . If female , participant pregnant lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period . 25 . The participant participate another clinical study within past 30 day . 26 . The participant history extracorporeal external counterpulsation treatment chronic stable angina within 3 month prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>